Regeneron Pharmaceuticals, Inc.
REGN
$645.57
-$1.30-0.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.84% | 18.49% | |||
| Total Other Revenue | 7.78% | 124.54% | |||
| Total Revenue | 2.14% | 21.36% | |||
| Cost of Revenue | 2.29% | 8.94% | |||
| Gross Profit | 1.97% | 39.35% | |||
| SG&A Expenses | 3.72% | 0.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.25% | 6.66% | |||
| Operating Income | 1.87% | 80.38% | |||
| Income Before Tax | 16.11% | 67.81% | |||
| Income Tax Expenses | 138.63% | 31.98% | |||
| Earnings from Continuing Operations | 4.92% | 72.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.92% | 72.08% | |||
| EBIT | 1.87% | 80.38% | |||
| EBITDA | 1.80% | 67.55% | |||
| EPS Basic | 6.43% | 74.70% | |||
| Normalized Basic EPS | 0.64% | 66.97% | |||
| EPS Diluted | 6.32% | 76.20% | |||
| Normalized Diluted EPS | 0.50% | 68.41% | |||
| Average Basic Shares Outstanding | -1.43% | -1.50% | |||
| Average Diluted Shares Outstanding | -1.29% | -2.34% | |||
| Dividend Per Share | 0.00% | 0.00% | |||
| Payout Ratio | -0.06% | -0.43% | |||